knowledge -WSS

knowledge

author：focus 2025-09-27 12:47:37 - browse：1418

Humana sign -- health business coverage from STAT — Humana’s Medicare Advantage business is faring even worse than the company let on last week. Ed Reinke/AP

Humana’s Medicare Advantage business is faring even worse than the company let on last week, with “unprecedented” numbers of older adults getting medical care and busting through its tactics for holding up payment.

The country’s second largest private Medicare insurer disclosed Thursday it’s projecting roughly half the profit in 2024 that investors had expected. The news comes a week after Humana already lowered its projected 2023 profit, which still came in at north of $3 billion before taxes.

The stock market’s punishment was swift and decisive, sinking Humana’s share price by roughly 12% at midday. Outgoing CEO Bruce Broussard worked to calm nerves on the company’s investor call, reiterating his confidence in MA. Humana went all-in on the program when it announced last year it would wind down its employer business, but that comes as regulators are beefing up scrutiny of MA plans.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Vaccine advisory panel ACIP left half staffed by HHS

focus

WSS

Vaccine advisory panel ACIP left half staffed by HHS

KalVista pill reduced swelling 'attacks' caused by genetic disease

Biden report: The neurospychology of memory and aging

Patient advocates debate FDA's accelerated approval process

Scientists boost immune system in aging mice by making it youthful

Roche subsidiary Foundation Medicine opens new headquarters

focus

knowledge

knowledge

Activists slam private health insurers over coverage restrictions

Primary care physicians play key roles in Alzheimer's management

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How digital tools helped lower hypertension in marginalized patients

Medicare details structure of new drug price negotiation program

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Psychedelics group wrestles with new pharma identity

Primary care physicians play key roles in Alzheimer's management

Tori Bowie and the unacceptable rates of Black maternal death

Why the world’s most expensive drug might be worth the price

leisure time

Biogen Alzheimer’s drug launch off to slow start

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

The Readout: Gilead, Bernie Sanders, and other pharma news

Readout Newsletter: Merck, Vertex, and Viking updates

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Why the world’s most expensive drug might be worth the price

knowledge

hotspot

focus

focus